# Phase 1/2 Study of UI-102 in Selected Advanced Cancers

Source: https://onco.cc/trials/nct07605962/  
OnCo record `nct07605962` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of UI-102 in advanced solid tumours, run by United Immunity, co., Ltd., now recruiting.

## Summary

Phase 1/2 Study of UI-102 in Selected Advanced Cancers is a phase 1/2 interventional study registered as NCT07605962 by United Immunity, co., Ltd., with 140 participants planned, started 2026-05-20 and due to reach its primary completion in 2030-03-31. Interventions recorded: UI-102.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT07605962
- Phase: 1/2
- Setting: A Phase I/II Open-Label, Dose Escalation, Dose Optimization, and Cohort Expansion Trial to Investigate the Safety, Pharmacokinetics and Pharmacodynamics of UI-102, a Novel Cholesteryl Pullulan (CHP) Nanoparticle-formulated TLR7/8 Agonist in Patients With Selected Locally Advanced and/or Metastatic Solid Tumors
- Sponsor: United Immunity, co., Ltd.
- Enrolled: 140

## Sources

- ClinicalTrials.gov NCT07605962: https://clinicaltrials.gov/study/NCT07605962

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)

---
JSON: https://onco.cc/api/v1/entities/nct07605962.json